Genentech: Phase III study of tiragolumab combination in advanced lung cancer fails to meet its primary objective

SOUTH SAN FRANCISCO (dpa-AFX) – Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab combined with Tecentriq (atezolizumab) versus Tecentriq alone in patients with PD-L1 non-small cell lung high, locally advanced or metastatic cancer, did not reach the primary endpoint of overall survival in final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified.

Genentech, a member of the Roche Group (RHHBY), said it continually reviews its study programs to determine whether adjustments are necessary for the purposes of ongoing research. The company will apply the same principles to this program, with additional data from phase III studies in different settings or tumor types expected next year.

SKYSCRAPER-01 is a global phase III, randomized, double-blind study evaluating tiragolumab plus Tecentriq versus Tecentriq alone in 534 patients with previously untreated, locally advanced unresectable or metastatic PD-L1-high NSCLC. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq until disease progression, loss of clinical benefit, or unacceptable toxicity.

For more health news, visit rttnews.com.